Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open, Positives Parallel-controlled, Multicenter Phase III to Evaluate the Efficacy and Safety of FHND9041 Versus Afatinib in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

NCT06759857 is registered in ClinicalTrials.gov with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06759857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06759857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open, Positives Parallel-controlled, Multicenter Phase III to Evaluate the Efficacy and Safety of FHND9041 Versus Afatinib in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
August 1, 2021
Completion date
May 1, 2025
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer